- Home
- CRVS vs MSB Comparison
CRVS vs MSB Comparison
Compare CRVS & MSB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRVS
- MSB
- Stock Information
- Founded
- CRVS 2014
- MSB 1961
- Country
- CRVS United States
- MSB United States
- Employees
- CRVS N/A
- MSB N/A
- Industry
- CRVS Biotechnology: Pharmaceutical Preparations
- MSB Metal Mining
- Sector
- CRVS Health Care
- MSB Basic Materials
- Exchange
- CRVS Nasdaq
- MSB Nasdaq
- Market Cap
- CRVS 335.1M
- MSB 379.4M
- IPO Year
- CRVS 2016
- MSB N/A
- Fundamental
- Price
- CRVS $4.19
- MSB $28.32
- Analyst Decision
- CRVS Strong Buy
- MSB
- Analyst Count
- CRVS 5
- MSB 0
- Target Price
- CRVS $12.38
- MSB N/A
- AVG Volume (30 Days)
- CRVS 419.4K
- MSB 128.3K
- Earning Date
- CRVS 03-18-2025
- MSB 01-01-0001
- Dividend Yield
- CRVS N/A
- MSB 24.47%
- EPS Growth
- CRVS N/A
- MSB 714.88
- EPS
- CRVS N/A
- MSB 7.00
- Revenue
- CRVS N/A
- MSB $26,785,162.00
- Revenue This Year
- CRVS N/A
- MSB N/A
- Revenue Next Year
- CRVS N/A
- MSB N/A
- P/E Ratio
- CRVS N/A
- MSB $4.04
- Revenue Growth
- CRVS N/A
- MSB 85.21
- 52 Week Low
- CRVS $1.30
- MSB $15.93
- 52 Week High
- CRVS $10.00
- MSB $37.00
- Technical
- Relative Strength Index (RSI)
- CRVS 28.71
- MSB 52.65
- Support Level
- CRVS $4.60
- MSB $24.37
- Resistance Level
- CRVS $5.19
- MSB $32.54
- Average True Range (ATR)
- CRVS 0.30
- MSB 1.59
- MACD
- CRVS -0.06
- MSB 0.49
- Stochastic Oscillator
- CRVS 2.01
- MSB 55.34
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers, and autoimmune diseases. The company's primary product candidate is Soquelitinib (CPI-818), an oral, small-molecule drug that selectively inhibits ITK (interleukin-2-inducible T cell kinase). The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).
About MSB Mesabi Trust
Mesabi Trust operates as a royalty trust in the United States. The company is involved in the conservation and protection of the assets held. The company's principally wholly-owned segment is the iron ore mining segment and it generates income from the Peter Mitchell Mine, an iron mine located near Babbitt, Minnesota, at the eastern end of the Mesabi Iron Range.